Sending HPV self-collection tests by mail and providing support to schedule in-clinic screening appointments for under-screened women increased cervical cancer screening rates by almost two times.
A recent analysis found sexual minority individuals less likely to undergo cervical cancer screening than their heterosexual counterparts.
Researchers have made new findings, which may improve detection of the human papillomavirus (HPV) in the bloodstream.
How p16 and Ki-67 indicate transforming HPV infections.
Read More
Emerging techniques could help detect the virus leading to cervical cancer in low-income areas and developing nations.
Read More
The Hologic Genius Digital Diagnostics System is expected to derive even more actionable insights from cytology slides for cytotechnologists and pathologists with Google Cloud.
Read More
New survey results show strong support for this standby of cervical cancer screening.
Read More
The new point-of-care biomarker test detects levels of a specific antibody (DRH1) to HPV16. The study shows a link between rising levels of these HPV antibodies and cancer.
Read More
Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence algorithm with advanced digital imaging to help identify precancerous lesions and cancer cells.
Read More
A board-certified obstetrician and gynecologist expresses his concerns about the new ACS cervical cancer screening guidelines.
Read More
BD received a pre-market approval supplement from the FDA for an expanded version of its BD Onclarity HPV Assay.
Read More
Cotesting outperforms HPV or Pap testing alone in detecting cancer and precancer in women 30 years and older.
Read More
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read More
The test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus DNA in cervical samples.
Read More
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read More
CINtec Plus cytology is the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus using the Cobas 4800 HPV test.
Read More
The new human papillomavirus assay is a real-time polymerase chain reaction-based test that detects 15 recognized high-risk genotypes of HPV DNA.
Read More